A number of recent studies suggest that several molecules that affect angiogenesis and tumour growth act through cell surface NCL, such as hepatocyte growth factor [45], VEGF [46], endostatin [47,48] and tumour necrosis factor-alpha inducing protein [49], favouring the notion that targeting of cell surface NCL may prove to be an effective anticancer therapy [50,51]. This evidence concerns the gene VEGFA and neoplasm.